6496 Stock Overview
Develops and sells pharmaceutical products in Taiwan, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Excelsior Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.15 |
| 52 Week High | NT$40.15 |
| 52 Week Low | NT$26.70 |
| Beta | 0.35 |
| 1 Month Change | 6.46% |
| 3 Month Change | 7.35% |
| 1 Year Change | 13.81% |
| 3 Year Change | 7.17% |
| 5 Year Change | -7.61% |
| Change since IPO | -52.29% |
Recent News & Updates
Recent updates
Be Wary Of Excelsior Biopharma (GTSM:6496) And Its Returns On Capital
Apr 01
Is Excelsior Biopharma Inc. (GTSM:6496) An Attractive Dividend Stock?
Mar 11Is Excelsior Biopharma (GTSM:6496) Using Too Much Debt?
Feb 09Are Poor Financial Prospects Dragging Down Excelsior Biopharma Inc. (GTSM:6496 Stock?
Jan 11
Our Take On The Returns On Capital At Excelsior Biopharma (GTSM:6496)
Dec 22Here's Why Excelsior Biopharma's (GTSM:6496) Statutory Earnings Are Arguably Too Conservative
Nov 30Shareholder Returns
| 6496 | TW Healthcare | TW Market | |
|---|---|---|---|
| 7D | 1.1% | 0.2% | 1.2% |
| 1Y | 13.8% | -12.4% | 27.4% |
Return vs Industry: 6496 exceeded the TW Healthcare industry which returned -12.4% over the past year.
Return vs Market: 6496 underperformed the TW Market which returned 28% over the past year.
Price Volatility
| 6496 volatility | |
|---|---|
| 6496 Average Weekly Movement | 3.6% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6496 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6496's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Joseph Chen | www.excelsiorgroup.com.tw |
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases.
Excelsior Biopharma Inc. Fundamentals Summary
| 6496 fundamental statistics | |
|---|---|
| Market cap | NT$1.51b |
| Earnings (TTM) | -NT$70.69m |
| Revenue (TTM) | NT$830.35m |
1.8x
P/S Ratio-21.4x
P/E RatioIs 6496 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6496 income statement (TTM) | |
|---|---|
| Revenue | NT$830.35m |
| Cost of Revenue | NT$452.67m |
| Gross Profit | NT$377.68m |
| Other Expenses | NT$448.36m |
| Earnings | -NT$70.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 45.48% |
| Net Profit Margin | -8.51% |
| Debt/Equity Ratio | 10.8% |
How did 6496 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/27 04:03 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Excelsior Biopharma Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsiu Chi Lin | Masterlink Securities Corp. |